{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:27:10Z","timestamp":1777904830633,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Osteolytic bone disease, which deteriorates the quality of life, is a prevalent complication of multiple myeloma (MM). In this study, we utilized bioinformatics analysis to identify the differentially expressed genes (DEGs) associated with MM bone disease (MBD) from the Gene Expression Omnibus (GEO) databases. Here, the Kaplan-Meier (K-M) curve and Cox regression analyses demonstrated that the key molecule lymphocyte antigen 6 complex (LY6E) was closely correlated with the MM progression, unfavorable prognosis and the formation of MBD. Furthermore, we confirmed that higher LY6E expression promoted MM cell proliferation and osteoclast differentiation in vitro. Taken together, these findings may illuminate the theoretical foundation for LY6E in MBD formation and identify it as a neoteric therapeutic target for MM.<\/jats:p>","DOI":"10.1038\/s41598-025-91413-1","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:45:46Z","timestamp":1743803146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LY6E as a new prognostic biomarker of multiple myeloma-related bone disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Min","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"91413_CR1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"91413_CR2","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura, K., Smyth, M. J. & Martinet, L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136, 2731\u20132740 (2020).","journal-title":"Blood"},{"key":"91413_CR3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 3, 17046 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"91413_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander, N. S. et al. Nccn Guidelines(R) insights: multiple myeloma, version 3.2022. J. Natl. Compr. Cancer Netw. 20, 8\u201319 (2022).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"91413_CR5","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Myeloma bone disease: from biology findings to treatment approaches. Blood 133, 1534\u20131539 (2019).","journal-title":"Blood"},{"key":"91413_CR6","doi-asserted-by":"crossref","unstructured":"Bernstein, Z. S., Kim, E. B. & Raje, N. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. Cells. 11, (2022).","DOI":"10.3390\/cells11152308"},{"key":"91413_CR7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: A review. Jama-J Am. Med. Assoc. 327, 464\u2013477 (2022).","journal-title":"Jama-J Am. Med. Assoc."},{"key":"91413_CR8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","volume":"101","author":"P Clezardin","year":"2021","unstructured":"Clezardin, P. et al. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol. Rev. 101, 797\u2013855 (2021).","journal-title":"Physiol. Rev."},{"key":"91413_CR9","doi-asserted-by":"crossref","unstructured":"Marino, S. & Roodman, G. D. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb Perspect. Med. 8, (2018).","DOI":"10.1101\/cshperspect.a031286"},{"key":"91413_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2018.03.011","volume":"118","author":"EV Morris","year":"2019","unstructured":"Morris, E. V. & Edwards, C. M. Bone marrow adiposity and multiple myeloma. Bone 118, 42\u201346 (2019).","journal-title":"Bone"},{"key":"91413_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).","journal-title":"Blood Cancer J."},{"key":"91413_CR12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos, E. et al. International myeloma working group recommendations for the treatment of multiple myeloma-Related bone disease. J. Clin. Oncol. 31, 2347\u20132357 (2013).","journal-title":"J. Clin. Oncol."},{"key":"91413_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1200\/JCO.2002.20.1.353","volume":"20","author":"O Sezer","year":"2002","unstructured":"Sezer, O., Heider, U., Jakob, C., Eucker, J. & Possinger, K. Human bone marrow myeloma cells express Rankl. J. Clin. Oncol. 20, 353\u2013354 (2002).","journal-title":"J. Clin. Oncol."},{"key":"91413_CR14","first-page":"1436","volume":"9","author":"U Heider","year":"2003","unstructured":"Heider, U. et al. Expression of receptor activator of nuclear factor kappab ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin. Cancer Res. 9, 1436\u20131440 (2003).","journal-title":"Clin. Cancer Res."},{"key":"91413_CR15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","volume":"25","author":"NS Raje","year":"2019","unstructured":"Raje, N. S., Bhatta, S. & Terpos, E. Role of the Rank\/Rankl pathway in multiple myeloma. Clin. Cancer Res. 25, 12\u201320 (2019).","journal-title":"Clin. Cancer Res."},{"key":"91413_CR16","first-page":"1118","volume":"89","author":"N Giuliani","year":"2004","unstructured":"Giuliani, N., Colla, S., Morandi, F. & Rizzoli, V. The rank\/rank ligand system is involved in Interleukin-6 and Interleukin-11 Up-Regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 89, 1118\u20131123 (2004).","journal-title":"Haematologica"},{"key":"91413_CR17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","volume":"9","author":"D Harmer","year":"2018","unstructured":"Harmer, D., Falank, C. & Reagan, M. R. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front. Endocrinol. 9, 788 (2018).","journal-title":"Front. Endocrinol."},{"key":"91413_CR18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel, H., Kocemba, K. A., Spaargaren, M. & Pals, S. T. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia 33, 1063\u20131075 (2019).","journal-title":"Leukemia"},{"key":"91413_CR19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using Real-Time quantitative Pcr and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"91413_CR20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2012-06-434019","volume":"120","author":"M Sebag","year":"2012","unstructured":"Sebag, M. Ccr1 Blockade and myeloma bone disease. Blood 120, 1351\u20131352 (2012).","journal-title":"Blood"},{"key":"91413_CR21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","volume":"12","author":"GJ Morgan","year":"2011","unstructured":"Morgan, G. J. et al. Effects of Zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (Mrc myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 12, 743\u2013752 (2011).","journal-title":"Lancet Oncol."},{"key":"91413_CR22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje, N. et al. Denosumab versus Zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, Double-Blind, Double-Dummy, randomised, controlled, phase 3 study. Lancet Oncol. 19, 370\u2013381 (2018).","journal-title":"Lancet Oncol."},{"key":"91413_CR23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/CORR.0000000000001749","volume":"479","author":"A Bozzo","year":"2021","unstructured":"Bozzo, A. et al. Which Bone-Modifying agent is associated with better outcomes in patients with skeletal metastases from lung cancer?? A systematic review and network Meta-Analysis. Clin. Orthop. Rel Res. 479, 2047\u20132057 (2021).","journal-title":"Clin. Orthop. Rel Res."},{"key":"91413_CR24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. Clusterprofiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"91413_CR25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"91413_CR26","doi-asserted-by":"crossref","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. Kegg for Taxonomy-Based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"91413_CR27","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020\u20132028 (2006).","journal-title":"Blood"},{"key":"91413_CR28","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","volume":"17","author":"N Raje","year":"2011","unstructured":"Raje, N. & Roodman, G. D. Advances in the biology and treatment of bone disease in multiple myeloma. Clin. Cancer Res. 17, 1278\u20131286 (2011).","journal-title":"Clin. Cancer Res."},{"key":"91413_CR29","doi-asserted-by":"crossref","unstructured":"Yu, J. & Liu, S. L. Emerging Role of Ly6E in Virus-Host Interactions. Viruses-Basel. 11, (2019).","DOI":"10.3390\/v11111020"},{"key":"91413_CR30","doi-asserted-by":"crossref","unstructured":"Yu, J., Murthy, V. & Liu, S. L. Relating Gpi-Anchored Ly6 Proteins Upar and Cd59 to Viral Infection. Viruses-Basel. 11, (2019).","DOI":"10.3390\/v11111060"},{"key":"91413_CR31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40246-016-0074-2","volume":"10","author":"CL Loughner","year":"2016","unstructured":"Loughner, C. L. et al. Organization, evolution and functions of the human and mouse Ly6\/Upar family genes. Hum. Genomics. 10, 10 (2016).","journal-title":"Hum. Genomics"},{"key":"91413_CR32","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1158\/1078-0432.CCR-15-0156","volume":"21","author":"J Asundi","year":"2015","unstructured":"Asundi, J. et al. An Antibody-Drug conjugate directed against lymphocyte antigen 6 complex, locus E (Ly6E) provides robust tumor killing in a wide range of solid tumor malignancies. Clin. Cancer Res. 21, 3252\u20133262 (2015).","journal-title":"Clin. Cancer Res."},{"key":"91413_CR33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1189\/jlb.0113014","volume":"94","author":"PY Lee","year":"2013","unstructured":"Lee, P. Y., Wang, J. X., Parisini, E., Dascher, C. C. & Nigrovic, P. A. Ly6 family proteins in neutrophil biology. J. Leukoc. Biol. 94, 585\u2013594 (2013).","journal-title":"J. Leukoc. Biol."},{"key":"91413_CR34","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/s41467-018-06000-y","volume":"9","author":"KB Mar","year":"2018","unstructured":"Mar, K. B. et al. Ly6E mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step. Nat. Commun. 9, 3603 (2018).","journal-title":"Nat. Commun."},{"key":"91413_CR35","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1158\/0008-5472.CAN-15-2654","volume":"76","author":"M AlHossiny","year":"2016","unstructured":"AlHossiny, M. et al. Ly6E\/K signaling to Tgfbeta promotes breast Cancer progression, immune escape, and drug resistance. Cancer Res. 76, 3376\u20133386 (2016).","journal-title":"Cancer Res."},{"key":"91413_CR36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fimmu.2019.00819","volume":"10","author":"G Upadhyay","year":"2019","unstructured":"Upadhyay, G. Emerging role of lymphocyte Antigen-6 family of genes in Cancer and immune cells. Front. Immunol. 10, 819 (2019).","journal-title":"Front. Immunol."},{"key":"91413_CR37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0961203308089694","volume":"17","author":"J Tang","year":"2008","unstructured":"Tang, J. et al. Increased expression of the type I Interferon-Inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients. Lupus 17, 805\u2013813 (2008).","journal-title":"Lupus"},{"key":"91413_CR38","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2184.2008.00554.x","volume":"41","author":"C Bresson-Mazet","year":"2008","unstructured":"Bresson-Mazet, C., Gandrillon, O. & Gonin-Giraud, S. Stem cell antigen 2: A new gene involved in the Self-Renewal of erythroid progenitors. Cell. Prolif. 41, 726\u2013738 (2008).","journal-title":"Cell. Prolif."},{"key":"91413_CR39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gutjnl-2014-307213","volume":"64","author":"X Wang","year":"2015","unstructured":"Wang, X., Yang, Y. & Huycke, M. M. Commensal Bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect. Gut 64, 459\u2013468 (2015).","journal-title":"Gut"},{"key":"91413_CR40","doi-asserted-by":"crossref","first-page":"65837","DOI":"10.18632\/oncotarget.11670","volume":"7","author":"CJ Yeom","year":"2016","unstructured":"Yeom, C. J. et al. Ly6E: A conductor of malignant tumor growth through modulation of the Pten\/Pi3K\/Akt\/Hif-1 Axis. Oncotarget 7, 65837\u201365848 (2016).","journal-title":"Oncotarget"},{"key":"91413_CR41","doi-asserted-by":"crossref","unstructured":"Gai, D. et al. Cst6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J. Clin. Invest. 132, (2022).","DOI":"10.1172\/JCI159527"},{"key":"91413_CR42","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3389\/fimmu.2018.01508","volume":"9","author":"M Tang","year":"2018","unstructured":"Tang, M., Tian, L., Luo, G. & Yu, X. Interferon-Gamma-Mediated osteoimmunology. Front. Immunol. 9, 1508 (2018).","journal-title":"Front. Immunol."},{"key":"91413_CR43","doi-asserted-by":"crossref","first-page":"1396122","DOI":"10.3389\/fimmu.2024.1396122","volume":"15","author":"S Li","year":"2024","unstructured":"Li, S., Liu, G., Hu, S. & Osteoporosis Interferon-Gamma-Mediated bone remodeling in osteoimmunology. Front. Immunol. 15, 1396122 (2024).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91413-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91413-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:46:40Z","timestamp":1743803200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91413-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91413"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91413-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11431"}}